High Dose BAYA1040_Nifedipine: a Dose-comparative Study
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This is a clinical study evaluating the superiority in efficacy and assess safety and
tolerability of BAYA1040_Nifedipine 80 mg/day (40 mg twice daily) compared with
BAYA1040_Nifedipine 40 mg/day (40 mg once daily) in patients with essential hypertension who
are not at target blood pressure by BAYA1040_Nifedipine 40 mg once daily treatment.